Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidant contractor subpoenaed

This article was originally published in The Gray Sheet

Executive Summary

Contract manufacturer Accellent announces it has received a subpoena from the U.S. Attorney's Office in Minneapolis in a Nov. 21 8-K filing with the Securities & Exchange Commission. The subpoena, issued Oct. 28, requests documents relating to polyimide products the firm produces, which Guidant uses as an insulator for implantable cardioverter defibrillators and in other products. The New York Times has previously reported that the deterioration of this material under certain conditions might have played a role in some of the ICD malfunctions reported by the company during the past six months. The Accellent subpoena is connected with an investigation by the Attorney's Office relating to several of the firm's ICD products (1"The Gray Sheet" Oct. 31, 2005, p. 3)...

You may also be interested in...

Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation

Subpoenas served to Guidant, Medtronic and St. Jude Medical by the U.S. Department of Justice appear to be investigating potential improper inducements to increase sales of pacemakers and ICDs

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.

Keeping Track: Return & Renewal At US FDA

Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts